Cole Maguire
-
“Prolific Activation of a Network-Immune Inflammatory Crisis in severe COVID-19” Journal of the Neurological Sciences
Dr. Esther Melamed co-authored “Part I. SARS-CoV-2 triggered ‘PANIC’ attack in severe COVID-19,” a review on Prolific Activation of a Network-Immune Inflammatory Crisis (PANIC) published in the Journal of the Neurological Sciences. You can read the paper here.
-
SARS-CoV-2 specific antibody studies begin
This week, Hydroxychloroquine was brought to the forefront of the drug arena for COVID once again after retraction of a study that reported detrimental effects of the drug (Mehra et al., The Lancet 2020). This study from the Lancet has been called into question after a lack of transparency with data, with the authors (who…
-
ACTT releases Remdesivir report, advancement of Moderna vaccine, and new combination therapies being tested
In exciting news, the official report of the ACTT trial for Remdesivir was published in the New England Journal of Medicine this week (Beigel JH, et al.). In the study, we saw an expansion of the previously released preliminary results with stronger significance for the efficacy of Remdesivir on reducing time to recovery in a…
-
The potential for corticosteroid treatment in COVID-19?
Following the preliminary results from COVID-19 trials in the previous weeks, ongoing trials are continuing to be revamped and redesigned. So while we wait for additional news, this week’s blog post is going to focus on the debate of corticosteroids as a COVID-19 treatment. Corticosteroids are used for a variety of conditions such as asthma,…
-
New NIH Trial Announcements and another Hydroxychloroquine fails to find a beneficial effect in COVID-19
Several surprising announcements were made this past week pertaining to COVID-19 clinical trials. The first was the ending of the first phase of the NIAID ACTT trial of remdesivir. Although remdesivir did reduce recovery time from COVID-19 it did not demonstrate a significantly better mortality rate; thus, NIAID has begun the next phase of ACTT,…
-
Hydroxychloroquine produces no results in New York trials
This past week, new studies have shed light onto the risks/benefits and efficacy of hydroxychloroquine and remdesivir. For hydroxychloroquine, the preliminary data from New York’s recent clinical trial was published in the New England Journal of Medicine on Thursday (Geleris J, et al. 2020). This study was the largest to date (n=1,376), and tested both…
-
Remdesivir produces positive results in two trials
This week, there have been exciting updates about two Remdesivir trials with promising results. The first was NIAID’s ACT trial (n=800) which demonstrated a reduction in the time to recovery from 15 days to 11 days in the Remdesivir treated group compared to a control placebo (p < 0.001, NIAID ACTT). In addition, the trial…
-
Remdesivir as a potential emerging therapy and the possible dangers of hydroxychloroquine?
This week, there has been news for both remdesivir and chloroquine/ hydroxychloroquine. Following the announcement of preliminary results from the Gilead Science trials at the University of Chicago, there has been thought to be a promising potential in remdesivir with the trial now rapidly expanding. There has also been further speculation on preemptively released results…